TO THE EDITOR
Real-time quantitative PCR (RQ-PCR) is rapidly becoming a standard practice, which provides a sensitive and reproducible measurement of relative gene expression by comparing one or more genes of interest to a known internal control for normalization. RQ-PCR is widely used for detection of minimal residual disease in hematologic malignancies. 1, 2 In oncohematology, the typical example of the use of RQ-PCR is represented by the dosage of BCR-ABL transcript in positive BCR-ABL leukaemias, which makes it possible to appreciate the effectiveness of the innovating treatments such as Imatinib mesylate (STI571) (inhibiting the activity tyrosine kinase of ABL). 3 A collaborative action within the Europe Against Cancer (EAC) program defined and standardized RQ-PCR protocols suitable for measuring the level of fusion gene (FG) transcripts in leukemia. 4, 5 This standardized protocol developed on ABI 7700 s (Applied Biosystems) was used in the present study to evaluate and compare the technical outcomes of six RQ-PCR machines in the context of fusion gene transcript monitoring.
The current quantitative PCR machines on the market may be classified into two different categories according to the needs of the users: low-and high-throughput instruments. The low-throughput instruments are systems more appropriate to smaller batch samples, but are faster and generally present more flexibility, allowing the user to record different parameters. The high-throughput instruments (96-well-plate format) have been designed for laboratories running large series of samples and few differing parameters. In the present study, six RQ-PCR machines were compared to ABI 7700 s (Applied Biosystems) considered as the reference machine, since this was used for the development of the EAC protocol. The principal characteristics of these seven machines are referred to in Table 1 .
The evaluation of RQ-PCR machines was done using 1 : 10 serial dilutions of RNA from fusion gene transcripts (FT)-positive cell lines into RNA from HL60 cells (negative for fusion transcripts). For detection of BCR-ABL M-bcr, m-bcr and AML1-ETO fusion gene transcripts, K562, TOM-1 and Kasumi cell lines were used, respectively. For each of the six machines, repeatability, reproducibility and sensitivity were measured, using the Europe Against Cancer (EAC) standardized protocol. 4 Quantification was performed by the use of plasmid standard curves (Ipsogen, France). Results were expressed as normalized copy number (NCN; fusion gene transcript copy number/control gene copy number). 5 The sensitivity of the different machines was evaluated on fusion transcript detection. First, this was determined on 10 copies of plasmid dilutions, which were run for each FT determination. Second, we compared the detection of FT expression in cell line serial dilutions of RNA in RNA (five dilutions from 10 À1 to 10 À5 ) by each evaluated machine vs our reference machine (ABI 7700 s ). We observed that an amplification of the 10 copies plasmid dilution was observed in more than 90% of the experiments whatever the RQ-PCR machine used, and that PCR efficiencies (ie standard curve slope) did not differ on the seven RQ-PCR machines used (not shown). Moreover, we noticed that each time a sample was positive for FT amplification on the reference machine, it was equally positive on the evaluated machine (not shown). This indicates that in terms of sensitivity the different RQ-PCR machines are equivalent.
Repeatability and reproducibility measurements were performed for each control gene (E10 5 copies) and for fusion transcripts (E10 5 and 10 2 copies). Each sample was analyzed 10 times in a single experiment (repeatability) or five times in duplicate in five successive experiments (reproducibility). Ct values were collected and the calculated coefficient of variation (CV in %) for each mentioned copy number is reported in Table 2 (raw data are available at http://meidia.nord.univ-mrs.fr). Except for Smart Cycler in repeatability measurement (2.14), all of the CVs were less than 2%, showing very low intra-assay and inter-assay variations.
For comparison of NCN, each sample (cDNA from RNA dilutions from E10 5 to 10 copies) was analyzed in parallel on the evaluated machine and ABI 7700 s . Standard curves allowed determination of copy number (CN) for each transcript. For each RQ-PCR instrument, NCN obtained was compared to those of ABI 7700 s . A statistical analysis was performed on results obtained from the five dilutions of the three cell lines. The General Linear Model (GLM) multivariate provides regression analysis and analysis of variance for multiple dependent variables (NCN for BCR-ABL and AML1-ETO) by one or more factor variables (RQ-PCR machine or control gene used for normalization). The GLM multivariate procedure revealed no statistically significant difference in NCN regarding either the machine considered or the control gene, that is, Abelson (ABL), beta-glucuronidase (GUS) or transcription factor IID (TBP) used for normalization (GLM multivariate results are available at http://meidia.nord.univ-mrs.fr).
Furthermore, the organization of a workshop allowed the multicentric comparison of RQ-PCR analysis (Figure 1) . In all, 17 laboratories expert in molecular biology in oncohematology were involved in this workshop organized by the Groupe de Biologie Moléculaire des Hémopathies Malignes (GBMHM); 2/3 of them had no experience or less than 6 months experience in RQ-PCR. We report here the data of the 10 of those which have analyzed the expression of BCR-ABL M-bcr. Samples were centrally prepared and consisted of RNAs positive for either BCR-ABL M-bcr diluted (1/1000) or not in HL60 RNA. Each laboratory received RNA samples, plasmids and 20 Â concentrated primer and probe mix (defined by EAC) for ABL and BCR-ABL M-bcr measurement by RQ-PCR. Reverse transcription was performed by each participant according to the EAC protocol, 4 with some local modifications regarding the enzyme used (either MMLV or Superscript II or AMV). RQ-PCR amplifications were performed by each laboratory following EAC recommendations. Samples prepared from K562 cells were analyzed on either 7000 s (labs #3 and #17), or ABI 7700 s (labs #8, #12 and #16), or iCycler s (lab #4), or LightCycler s (labs #2, #9, #11 and #15). As previously described, quantification was performed using plasmid dilutions and NCN was calculated for each sample. The results for BCR-ABL M-bcr are excellent for this multicentric analysis, taking into account the inexperience of operators and the variability of reverse transcriptase used (either Superscript, MMLV or AMV). CV values for NCN are less than 20% in both pure and diluted sample.
This evaluation gives an idea of the effectiveness of these machines (i) in the application of the EAC protocol without optimized methods for the different RQ-PCR machines and (ii) at a precise time. Indeed, some apparatuses such as opticon (MJ Research); the MX3000 (Stratagene) or the recently developed Light Cycler 2.0 (retaining the advantages of the Light Cycler; it offers greater possibilities for fluorophore use since six detection channels are available and two capillary formats (100 and 20 ml)) could not be included in this study. All the tested machines in the present study were identical in terms of performance. Thus, the choice of investing in the available machines should rather be based on local priorities. It should be noted that the machines with a low capacity are less adapted to this EAC protocol because of numerous wells used for different standard curves and controls. Consequently, commercial strategies are considered for solving the problem of capacity by proposing other methods of quantification. For example, Roche Molecular Biochemicals has included a Calibrator RNA and a positive control in its detection kit to replace calibration curves.
Our results show that RQ-PCR is a robust technology and that the EAC standardized protocol can be transferred to the different machines without any modifications. The assays enable reliable quantification on all the instruments, producing calibration curves with strong correlation and presenting the same sensitivity on 10 copies of molecules. We show that the EAC protocol is applicable by laboratories expert in molecular biology on each of the seven tested machines. This study may serve as an example for the dosage by RQ-PCR of any gene transcript. 
Figure 1
Normalized copy numbers (NCNs) for BCR-ABL M-bcr amplification in multicentric workshop. The same RNA samples were analyzed for BCR-ABL M-bcr and ABL amplification in 10 laboratories using four different RQ-PCR machines. Copy numbers were obtained using plasmid standard curves and NCN (BCR-ABL M-bcr copy number/ABL copy number) was calculated for each laboratory.
